Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Descriptor ID |
D010975
|
| MeSH Number(s) |
D27.505.954.502.780
|
| Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Warfarin, not direct oral anticoagulants or antiplatelet therapy, is associated with increased bleeding risk in emergency general surgery patients: Implications in this new era of novel anticoagulants: An EAST multicenter study. J Trauma Acute Care Surg. 2024 Aug 01; 97(2):225-232.
-
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
-
Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial. Cardiovasc Diabetol. 2019 06 07; 18(1):77.
-
The calculus of preloading antiplatelet agents in ST-elevation myocardial infarction: Does it make a difference? Catheter Cardiovasc Interv. 2019 03 01; 93(4):602-603.
-
Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. Cardiovasc Drugs Ther. 2018 10; 32(5):443-451.
-
Why we need intravenous antiplatelet agents. Future Cardiol. 2016 09; 12(5):553-61.
-
Antiplatelet agents in transradial primary PCI: safe enough to be aggressive. Coron Artery Dis. 2016 06; 27(4):255-6.
-
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 03; 133(18):1772-82.
-
Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction and Concurrent Active Gastrointestinal Bleeding. Circ Cardiovasc Interv. 2015 Oct; 8(10).
-
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation. 2015 Jan 06; 131(1):62-73.